Self-Reported Long-Term Side Effects of Isotretinoin: A Case Series
isotretinoin In this brief communication, JDD authors T. Roxana Ghadimi BS, Michael J. Martinez BS, and Evan A. Rieder MD present self-reported long-term, remote side effects to isotretinoin that dermatologists must be aware of. INTRODUCTION Isotretinoin is considered the gold standard treatment for severe nodulocystic acne, though it has been the subject of controversy in the media for concerns relate …
isotretinoin
Latest Therapies for Psoriasis | Practical Pearls from The Expert
psoriasisNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Han shares why it’s an exciting time to treat psoriasis, and why the developments of the past year have bolstered the clinician’s armamentarium. Watch and lear …
psoriasis
Mental Health Effects of Eczema | The Expert Weighs In
ECZEMASELF recently posted an article about the hidden mental health effects of eczema. How should dermatology clinicians approach their eczema patients about the mental impacts of this skin condition? When should a dermatologist refer to a mental health professional? For expert advice, I reached out to dermatologist and clinical psychologist Richard Fried, MD, PhD, clinical director of Yardley Derm …
ECZEMA
Paging Pediatric Dermatology to the Emergency Room!
Pediatric Dermatology EmergenciesPediatric dermatologic emergencies are very real, highlights Dr. Kalyani Marathe, Associate Professor of Dermatology and Pediatrics at the University of Cincinnati, who lectured during ODAC 2023. Pediatric dermatologic emergencies represent almost 4% of emergency room visits, and of those, most are related to chronic skin disease, drug eruptions, and infections. Here, we will review some of those …
Pediatric Dermatology Emergencies
Tapinarof Therapeutic Cheat Sheet
TAPINAROFTapinarof cream is a non-steroidal topical medication that was recently FDA approved in 2022 for the treatment of mild, moderate, or severe plaque psoriasis in adult patients. As biologic medications have continued to grow and become exceedingly present in the treatment of moderate to severe psoriasis, there has been very minimal, if any innovation in the space of topical treatments. Additionally, …
TAPINAROF